Evotec SE (EVO) Cash from Financing Activities (2021 - 2026)
Evotec SE's (EVO) quarterly Cash from Financing Activities came in at -$22349.5 in Q1 2026, down 159.97% year-on-year from $37267.2 in Q1 2025, and up 99.95% quarter-over-quarter from -$43.8 million in Q4 2025.
Evotec SE (EVO) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Evotec SE has disclosed Cash from Financing Activities across 6 years of filings, most recently posting -$22349.5 for Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$22349.5, down 159.97% year-over-year; the trailing twelve-month figure through Mar 2026 was -$43.9 million (up 74.56% YoY), and the FY2025 annual result was -$43.8 million, up 74.61% from the prior year.
- Cash from Financing Activities came in at -$22349.5 for Q1 2026 at Evotec SE, up from -$43.8 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $77.4 million in Q4 2023 to a low of -$172.4 million in Q4 2024.
- The 5-year median for Cash from Financing Activities is -$7889.6 (2024), against an average of -$11.7 million.
- Across the five-year window, Cash from Financing Activities surged 991.27% in 2023 and plunged 1780.81% in 2024, its largest moves.
- Evotec SE's Cash from Financing Activities stood at -$59.3 million in 2022, then jumped by 230.55% to $77.4 million in 2023, then plunged by 322.75% to -$172.4 million in 2024, then surged by 74.58% to -$43.8 million in 2025, then soared by 99.95% to -$22349.5 in 2026.
- The last three Cash from Financing Activities figures came in at -$22349.5 (Q1 2026), -$43.8 million (Q4 2025), and -$14185.3 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Evotec SE | 570.60 Mn | 570.08 Mn | - | -22,349.53 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22,349.53 |
| Mar 31, 2026 | -22,349.53 |
| Dec 31, 2025 | -43.81 Mn |
| Dec 31, 2025 | -43.81 Mn |
| Sep 30, 2025 | -14,185.31 |
| Sep 30, 2025 | -14,185.31 |
| Jun 30, 2025 | -16,635.28 |
| Jun 30, 2025 | -16,635.28 |
| Mar 31, 2025 | 37,267.21 |
| Mar 31, 2025 | 37,267.21 |
| Dec 31, 2024 | -172.35 Mn |
| Dec 31, 2024 | -172.35 Mn |
| Sep 30, 2024 | -7,889.61 |
| Sep 30, 2024 | -7,889.61 |
| Jun 30, 2024 | -128,192.70 |
| Jun 30, 2024 | -128,192.70 |
| Mar 31, 2024 | -6,378.03 |
| Mar 31, 2024 | -6,378.03 |
| Dec 31, 2023 | 77.38 Mn |
| Dec 31, 2023 | 77.38 Mn |